Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Introduction: Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. Anlotinib is a multi-kinase inhibitor targeting VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jianhui, Song, Yan, Shou, Jianzhong, Bai, Yuxian, Li, Hanzhong, Xie, Xiaodong, Luo, Hong, Ren, Xiubao, Liu, Jiyan, Ye, Dingwei, Bai, Xianzhong, Fu, Cheng, Qin, Shukui, Wang, Jinwan, Zhou, Ai-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221023/
https://www.ncbi.nlm.nih.gov/pubmed/32457838
http://dx.doi.org/10.3389/fonc.2020.00664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221023/
https://www.ncbi.nlm.nih.gov/pubmed/32457838
http://dx.doi.org/10.3389/fonc.2020.00664

Ejemplares similares